Abstract
Plasma free captopril concentrations and haemodynamic response to captopril were studied in 20 patients with severe chronic heart failure. A 25 mg oral dose of captopril produced a 36% reduction in systemic vascular resistance, with individual responses varying from 13% to 64%. Mean systemic pressure fell by 20% and cardiac output rose 28%. The absorption of captopril was rapid. Peak plasma free captopril concentration occurred at 45 minutes after the dose and was followed by a smaller second peak. Peak plasma free captopril concentrations varied more than 20-fold but did not correlate with the maximal reduction in systemic vascular resistance. Elimination half life was seven hours. Fourteen patients were restudied after 1-2 months of captopril treatment and 12 showed symptomatic benefit. There was a sustained improvement in haemodynamic state and in non-invasive indices of myocardial function. During long term treatment the predose plasma free captopril concentration correlated well with dosage, but steady state captopril concentrations did not show a significant relation with haemodynamic response. On a dosage regimen of 25-50 mg three times daily the morning predose plasma free captopril concentration and plasma renin activity were relatively low and suggested that maximal inhibition of the renin-angiotensin system was not maintained throughout the dosage interval.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cleland J. G., Dargie H. J., Robertson J. I., Ball S. G., Hodsman G. P. The use of captopril in the management of cardiac failure. Scott Med J. 1984 Apr;29(2):129–130. [PubMed] [Google Scholar]
- Cody R. J., Covit A., Schaer G., Williams G. Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe chronic congestive heart failure. Am Heart J. 1982 Nov;104(5 Pt 2):1180–1183. doi: 10.1016/0002-8703(82)90048-5. [DOI] [PubMed] [Google Scholar]
- Cohn J. N., Levine T. B. Angiotensin-converting enzyme inhibition in congestive heart failure: the concept. Am J Cardiol. 1982 Apr 21;49(6):1480–1483. doi: 10.1016/0002-9149(82)90364-2. [DOI] [PubMed] [Google Scholar]
- Dargie H. J., Ball S. G., Atkinson A. B., Robertson J. I. Converting enzyme inhibitors in hypertension and heart failure. Br Heart J. 1983 Apr;49(4):305–308. doi: 10.1136/hrt.49.4.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Drury P. L., Edwards C. R. Studies on the cryoactivation of human renin. Clin Chim Acta. 1981 Jul 1;113(3):319–323. doi: 10.1016/0009-8981(81)90285-0. [DOI] [PubMed] [Google Scholar]
- Duncan F. M., Martin V. I., Williams B. C., Al-Dujaili E. A., Edwards C. R. Development and optimisation of a radioimmunoassay for plasma captopril. Clin Chim Acta. 1983 Jul 15;131(3):295–303. doi: 10.1016/0009-8981(83)90099-2. [DOI] [PubMed] [Google Scholar]
- Levine T. B., Franciosa J. A., Cohn J. N. Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation. 1980 Jul;62(1):35–41. doi: 10.1161/01.cir.62.1.35. [DOI] [PubMed] [Google Scholar]
- Romankiewicz J. A., Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs. 1983 Jan;25(1):6–40. doi: 10.2165/00003495-198325010-00002. [DOI] [PubMed] [Google Scholar]
- Wong K. K., Lan S., Migdalof B. H. In vitro biotransformations of [14C]captopril in the blood of rats, dogs and humans. Biochem Pharmacol. 1981 Oct 1;30(19):2643–2650. doi: 10.1016/0006-2952(81)90532-3. [DOI] [PubMed] [Google Scholar]